Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2013-02-19 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2013-02-19 English
SC 13G/A Filing
Major Shareholding Notification
2013-02-14 English
SC 13G/A Filing
Major Shareholding Notification
2013-02-14 English
SC 13G/A Filing
Major Shareholding Notification
2013-02-14 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing its financial results for the quarter ended December 31, 2012, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 2895 characters, which is relatively short and consistent with an announcement rather than a full earnings release. According to the rules, if a document is short and primarily announces or furnishes a press release of financial results, it should be classified as an Earnings Release (ER) if it contains key highlights, or Regulatory Filings (RNS) if it is just a filing of the press release without detailed financial data. Since the document is a Form 8-K furnishing a press release announcing quarterly financial results, it aligns best with an Earnings Release (ER).
2013-02-13 English
SC 13G Filing
Major Shareholding Notification
2013-02-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.